Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.

Mol Ther Oncolytics · 2023 · PMC10465858 · PMID 37654972

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The combination of rVSV-NDV-GFP with anti-CTLA-4 showed a trend of enhanced tumor control, especially in the directly injected tumors.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.